The conversation about hormones has become noisy enough that patients arriving at the practice often have questions shaped more by social media than by clinical evidence. That is understandable. The gap between what mainstream medicine has typically offered and what the wellness industry is willing to promise is wide, and patients looking for honest answers have had to navigate both extremes.
The clinical version of hormone optimization sits between those extremes and is grounded in specific principles. It starts with symptoms, not numbers. A patient reporting fatigue, reduced exercise capacity, cognitive changes, mood instability, sleep disruption, sexual dysfunction, or loss of muscle mass is describing a clinical picture that warrants evaluation. The evaluation uses laboratory assessment to understand the physiology, but the starting point is the human experience, not a deviation on a lab report.
For men, the evaluation covers total and free testosterone, sex hormone binding globulin, estradiol, luteinizing hormone, follicle stimulating hormone, and related markers. A total testosterone that falls in the lower quarter of the reference range may still be producing symptomatic deficiency in a specific individual. Reference ranges are statistical constructs. Clinical judgment is what translates numbers into decisions. A physician who treats the number without treating the patient is doing medicine poorly. A physician who treats the patient without measuring carefully is doing it worse.
The treatment decision, when it is appropriate, is individualized. Injectable testosterone, topical formulations, and pellets each have clinical advantages and limitations. Dosing is adjusted to the patient over time. Monitoring includes hematocrit, PSA, cardiovascular parameters, and ongoing assessment of symptomatic response. This is medical treatment with appropriate follow-through, not a quarterly refill shipped from a telehealth platform. Hormone optimization at a concierge practice is delivered within a physician relationship that includes everything downstream of the initial prescription.
For women, the picture is more complex and the conversation has been distorted for longer. A generation of women was told that hormone therapy carried unacceptable risks based on data that has since been substantially reinterpreted. Many women who would have benefited from treatment were denied it. Many others are still being told their perimenopausal and menopausal symptoms are things to tolerate rather than things to address. That is not where the evidence currently stands for appropriate candidates.
Evaluation for women includes estrogen, progesterone, testosterone, DHEA, and thyroid markers. The individual risk profile is assessed. Symptoms, medical history, family history, and preferences are discussed in depth. For women who are candidates, hormone therapy is delivered with the continuity and monitoring the treatment requires. Adjustments are made as circumstances change. The physician remains accessible throughout, not only at annual appointments.
Thyroid evaluation deserves separate mention because it is the area where standard care most often falls short. Most thyroid screening relies on TSH alone. For the majority of patients that is adequate, but a subset has symptoms and physiology that TSH does not capture. Free T3, free T4, reverse T3, and thyroid antibodies provide a more complete picture for patients whose clinical situation warrants it. A physician willing to evaluate thyroid function comprehensively and willing to treat optimally rather than minimally is rare enough to be worth specifically looking for.
The risks of hormone therapy deserve honest discussion. Testosterone therapy can affect hematocrit, cardiovascular parameters, and prostate health. Estrogen and progesterone therapy carry specific risk profiles that depend on age, delivery route, and individual risk factors. A physician who discusses hormones without discussing risks is not doing the job. A physician who refuses to discuss hormones because of outdated risk framing is also not doing the job. Clinical integrity requires both willingness to treat and willingness to discuss what treatment involves.
The Menopause Society publishes current clinical guidance that reflects the substantial reinterpretation of hormone therapy evidence over the last two decades. The current position is considerably more favorable to treatment in appropriate candidates than the guidance that dominated in the early 2000s, and patients whose last hormone conversation happened a decade ago deserve an updated one.
What the conversation with a physician should sound like is direct, specific, and calibrated to the individual. The patient’s symptoms are taken seriously. The laboratory work is comprehensive. The options are laid out with their evidence and their risks. The decision is made jointly and monitored over time. The physician is available when questions emerge. That is what Dr. Stein provides for members at Boca Raton Concierge Medicine, and it is what adults over 45 evaluating their hormonal health should expect from any physician offering this kind of care.
To discuss hormone evaluation directly, call (561) 483-5500 or reach the practice through the contact page.